The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases
- 1 January 2017
- journal article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 64 (7), 675-683
- https://doi.org/10.1507/endocrj.ej16-0587
Abstract
Diagnostic delay of tumor induced osteomalacia (TIO) is common in clinic practice. To investigate the diagnostic condition of TIO in China and raise clinicians’ awareness of TIO, we retrospectively analyzed clinical manifestations, biochemical features, and specially evaluated missed diagnoses and misdiagnoses among 144 TIO patients from Peking Union Medical College Hospital during December 1982 to December 2014. Clinical presentations of TIO mainly included bone pain, difficulty in walking, pathological fractures, muscle weakness, and height loss. TIO patients demonstrated hypophosphatemia (0.48±0.13 mmol/L), elevated serum alkaline phosphatase (277.9±152.6 U/L), reduced tubular maximum for phosphorus/glomerular filtration rate (0.39±0.14) and markedly elevated serum fibroblast growth factor 23 (FGF23) (median level 302.9 pg/mL). The average time from onset to a correct diagnosis was 2.9±2.3 years while the mean duration from onset to tumor resection was 5.4±4.2 years. The initial misdiagnosis rate was 95.1% (137/144) and 240 case-times of misdiagnoses occurred among the 144 cases. The most frequent misdiagnoses were intervertebral disc herniation, spondyloarthritis (including ankylosing spondylitis) and osteoporosis. A total of 43.1% (62/144) cases with hypophosphatemia presented on their laboratory sheets were neglected and missed diagnosed. Our study showed that TIO was frequently misdiagnosed and missed diagnosed due to its rarity, insidious onset, nonspecific clinical manifestations and clinicians’ poor recognition. It is necessary to test serum phosphorus in patients with musculoskeletal symptoms and difficulty in walking. The measurement of serum FGF23 is rather valuable. Once hypophosphatemia is discovered, TIO should be suspected and it is highly recommended to search for tumors and perform curative surgery.Keywords
This publication has 25 references indexed in Scilit:
- Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigmaEndocrine, 2016
- Tumour-induced osteomalacia: a literature review and a case reportWorld Journal of Surgical Oncology, 2015
- En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic reviewWorld Journal of Surgical Oncology, 2015
- The Phosphaturic Mesenchymal Tumor: Why is Definitive Diagnosis and Curative Surgery Often Delayed?Clinical Orthopaedics and Related Research, 2013
- Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literatureChinese Journal of Cancer, 2011
- Tumor-induced osteomalaciaEndocrine-Related Cancer, 2011
- Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic EntityThe American Journal of Surgical Pathology, 2004
- Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked HypophosphatemiaThe New England Journal of Medicine, 2003
- Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/OsteomalaciaJournal of Clinical Endocrinology & Metabolism, 2002
- Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalaciaProceedings of the National Academy of Sciences of the United States of America, 2001